Stemedica

STEMEDICA SECURES U.S. PATENT TO USE MULTIPLE STEM CELL LINES SIMULTANEOUSLY TO TREAT ISCHEMIC STROKE

Stemedica was issued a new patent entitled “Composition of Stem Cells and Stem Cell Factors for Their Use and Manufacture.” This patent covers a method for treating patients with ischemic stroke, and the treatment includes intrathecal administration of hypoxically grown neural stem cells and intravenous administration of hypoxically grown mesenchymal stem cells.

STEMEDICA EARNS U.S. PATENT FOR CELLULAR SCAFFOLD ENHANCED BY STEM CELL FACTORS

Stemedica received a new patent from the U.S. Patent & Trademark Office, US8709081 entitled “Cellular Scaffold.” This patent, coupled with the US8105380 patent issued in 2012, extends Stemedica’s proprietary technology to therapeutic skin regeneration.

More news >>

Transforming Medicine for the 21st Century

Stemedica Cell Technologies, Inc., is transforming regenerative medicine through the development and manufacturing of adult ischemic-tolerant stem cell products and biological compounds. Our technology has led us to breakthroughs that are changing medicine and improving life globally. As one of the few companies licensed and approved for clinical grade manufacturing and trial applications by regulatory agencies worldwide, our focus is on producing the best-in-class products available today.

Watch a short informative video about our company and the unique technological advantages of our proprietary adult stem cells.

Stemdica Overview Video

StemCutis

Unique stem cell-based products to treat dermatological diseases and improve the appearance of patients’ skin

The company is currently in clinical trials with therapies for photoaged skin. StemCutis is using stem cells and their factors to treat a range of conditions that affect skin and tissue appearance: compromised skin, diabetic ulcers, hair loss, burns and hypertrophic, hypotrophic and keloid scars.

Further information >>

Cardio Cell

Applying stem-cell technology for cardiovascular indications is not just an idea anymore.

CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products for cardiovascular indication.

Further information >>